Cargando…

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use

Polycystic liver disease (PLD) is a common extrarenal complication of autosomal dominant polycystic kidney disease (ADPKD), which causes compression-related syndrome and ultimately leads to liver dysfunction. Tolvaptan, a V2 receptor antagonist, is widely used to protect kidney function in ADPKD but...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Hiroki, Sekine, Akinari, Suwabe, Tatsuya, Ikuma, Daisuke, Yamanouchi, Masayuki, Hasegawa, Eiko, Sawa, Naoki, Ubara, Yoshifumi, Hoshino, Junichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853523/
https://www.ncbi.nlm.nih.gov/pubmed/35176098
http://dx.doi.org/10.1371/journal.pone.0264065
_version_ 1784653248277250048
author Mizuno, Hiroki
Sekine, Akinari
Suwabe, Tatsuya
Ikuma, Daisuke
Yamanouchi, Masayuki
Hasegawa, Eiko
Sawa, Naoki
Ubara, Yoshifumi
Hoshino, Junichi
author_facet Mizuno, Hiroki
Sekine, Akinari
Suwabe, Tatsuya
Ikuma, Daisuke
Yamanouchi, Masayuki
Hasegawa, Eiko
Sawa, Naoki
Ubara, Yoshifumi
Hoshino, Junichi
author_sort Mizuno, Hiroki
collection PubMed
description Polycystic liver disease (PLD) is a common extrarenal complication of autosomal dominant polycystic kidney disease (ADPKD), which causes compression-related syndrome and ultimately leads to liver dysfunction. Tolvaptan, a V2 receptor antagonist, is widely used to protect kidney function in ADPKD but its effect on PLD remains unknown. An observational cohort study was conducted to evaluate tolvaptan’s effect on patients with PLD due to ADPKD. After screening 902 patients, we found the 107 ADPKD patients with PLD who met the criteria of tolvaptan use in Japan. Among them, tolvaptan was prescribed for 62 patients (tolvaptan group), while the other was defined as the non-tolvaptan group. Compared with the non-tolvaptan group, the tolvaptan group had larger height-adjusted total kidney volume (median 994(range 450–4152) mL/m, 513 (405–1928) mL/m, p = 0.01), lower albumin level (mean 3.9±SD 0.4 g/dL, 4.3±0.4g/dL, p<0.01), and higher serum creatinine level (1.2±0.4 mg/dL, 0.9±0.2 mg/dL, p<0.01). Although the median change in annual growth rate of total liver volume (TLV) was not statistically different between the tolvaptan group (-0.8 (-15.9, 16.7) %/year) and the non-tolvaptan group (1.7 (-15.6–18.7) %/year)(p = 0.52), 20 (43.5%) patients in the tolvaptan group experienced a decrease in the growth rate of TLV (responders). A multivariable logistic regression model adjusting for related variables showed that older age (odds ratio 1.15 [95% CI 1.01–1.32]) and a higher growth rate of TLV in the non-tolvaptan period (odds 1.45 95% CI 1.10–1.90) were significantly associated with responders. In conclusion, the change in annual growth rate of TLV in ADPKD patients taking tolvaptan was not statistically different compared with that in ADPKD patients without taking tolvaptan. However, tolvaptan may have the potential to suppress the growth rate of TLV in some PLD patients due to ADPKD, especially in older patients or those that are rapid progressors of PLD. Several limitations were included in this study, therefore well-designed prospective studies were required to confirm the effect of tolvaptan on PLD.
format Online
Article
Text
id pubmed-8853523
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-88535232022-02-18 Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use Mizuno, Hiroki Sekine, Akinari Suwabe, Tatsuya Ikuma, Daisuke Yamanouchi, Masayuki Hasegawa, Eiko Sawa, Naoki Ubara, Yoshifumi Hoshino, Junichi PLoS One Research Article Polycystic liver disease (PLD) is a common extrarenal complication of autosomal dominant polycystic kidney disease (ADPKD), which causes compression-related syndrome and ultimately leads to liver dysfunction. Tolvaptan, a V2 receptor antagonist, is widely used to protect kidney function in ADPKD but its effect on PLD remains unknown. An observational cohort study was conducted to evaluate tolvaptan’s effect on patients with PLD due to ADPKD. After screening 902 patients, we found the 107 ADPKD patients with PLD who met the criteria of tolvaptan use in Japan. Among them, tolvaptan was prescribed for 62 patients (tolvaptan group), while the other was defined as the non-tolvaptan group. Compared with the non-tolvaptan group, the tolvaptan group had larger height-adjusted total kidney volume (median 994(range 450–4152) mL/m, 513 (405–1928) mL/m, p = 0.01), lower albumin level (mean 3.9±SD 0.4 g/dL, 4.3±0.4g/dL, p<0.01), and higher serum creatinine level (1.2±0.4 mg/dL, 0.9±0.2 mg/dL, p<0.01). Although the median change in annual growth rate of total liver volume (TLV) was not statistically different between the tolvaptan group (-0.8 (-15.9, 16.7) %/year) and the non-tolvaptan group (1.7 (-15.6–18.7) %/year)(p = 0.52), 20 (43.5%) patients in the tolvaptan group experienced a decrease in the growth rate of TLV (responders). A multivariable logistic regression model adjusting for related variables showed that older age (odds ratio 1.15 [95% CI 1.01–1.32]) and a higher growth rate of TLV in the non-tolvaptan period (odds 1.45 95% CI 1.10–1.90) were significantly associated with responders. In conclusion, the change in annual growth rate of TLV in ADPKD patients taking tolvaptan was not statistically different compared with that in ADPKD patients without taking tolvaptan. However, tolvaptan may have the potential to suppress the growth rate of TLV in some PLD patients due to ADPKD, especially in older patients or those that are rapid progressors of PLD. Several limitations were included in this study, therefore well-designed prospective studies were required to confirm the effect of tolvaptan on PLD. Public Library of Science 2022-02-17 /pmc/articles/PMC8853523/ /pubmed/35176098 http://dx.doi.org/10.1371/journal.pone.0264065 Text en © 2022 Mizuno et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Mizuno, Hiroki
Sekine, Akinari
Suwabe, Tatsuya
Ikuma, Daisuke
Yamanouchi, Masayuki
Hasegawa, Eiko
Sawa, Naoki
Ubara, Yoshifumi
Hoshino, Junichi
Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
title Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
title_full Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
title_fullStr Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
title_full_unstemmed Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
title_short Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
title_sort potential effect of tolvaptan on polycystic liver disease for patients with adpkd meeting the japanese criteria of tolvaptan use
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853523/
https://www.ncbi.nlm.nih.gov/pubmed/35176098
http://dx.doi.org/10.1371/journal.pone.0264065
work_keys_str_mv AT mizunohiroki potentialeffectoftolvaptanonpolycysticliverdiseaseforpatientswithadpkdmeetingthejapanesecriteriaoftolvaptanuse
AT sekineakinari potentialeffectoftolvaptanonpolycysticliverdiseaseforpatientswithadpkdmeetingthejapanesecriteriaoftolvaptanuse
AT suwabetatsuya potentialeffectoftolvaptanonpolycysticliverdiseaseforpatientswithadpkdmeetingthejapanesecriteriaoftolvaptanuse
AT ikumadaisuke potentialeffectoftolvaptanonpolycysticliverdiseaseforpatientswithadpkdmeetingthejapanesecriteriaoftolvaptanuse
AT yamanouchimasayuki potentialeffectoftolvaptanonpolycysticliverdiseaseforpatientswithadpkdmeetingthejapanesecriteriaoftolvaptanuse
AT hasegawaeiko potentialeffectoftolvaptanonpolycysticliverdiseaseforpatientswithadpkdmeetingthejapanesecriteriaoftolvaptanuse
AT sawanaoki potentialeffectoftolvaptanonpolycysticliverdiseaseforpatientswithadpkdmeetingthejapanesecriteriaoftolvaptanuse
AT ubarayoshifumi potentialeffectoftolvaptanonpolycysticliverdiseaseforpatientswithadpkdmeetingthejapanesecriteriaoftolvaptanuse
AT hoshinojunichi potentialeffectoftolvaptanonpolycysticliverdiseaseforpatientswithadpkdmeetingthejapanesecriteriaoftolvaptanuse